About: In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 2007 (uk) im November 2007 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en payares de 2007 (ast) scientific article published on 01 November 2007 (en)
publication date	wds:Q57374767-FC820151-7682-4A8E-81BC-2A0763801D24
publication date	2007-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57374767-6FC2C639-2844-4D3B-83AB-BFDE6AA546FA
language of work or name	English
cites work	wds:Q57374767-81A8CAF8-BA02-4F29-AEA3-8F56DA8B59AF
cites work	Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
author name string	wds:Q57374767-3E8168CB-4F7F-426F-8AF2-46C61B51783B wds:Q57374767-C8CC30F6-055A-4E13-9424-F79CAE388AFE wds:Q57374767-C993B991-EBBE-4361-BC40-19F86216D0FF wds:Q57374767-D5178DAD-9177-4F0F-99E8-E12D230CBF48 wds:Q57374767-DA0D360B-6922-4ABD-9128-F49246DBF447
author name string	Fleur Bossi Francesco Tedesco Roberto Marzari Sonia Zorzet Alberto Amadori
rdfs:label	In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (en) In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (nl)
skos:prefLabel	In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (en) In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (nl)
name	In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (en) In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab (nl)
author	wds:Q57374767-50258117-B215-4EEB-A3F9-FC3CF9025AB4 wds:Q57374767-BCFA19EF-E760-47AE-BCA3-04CD0F654FF5 wds:Q57374767-E4F40042-1D74-4C8B-A678-CB2851C69F94
author	Claudio Tripodo Paolo Macor Erich Piovan
title	wds:Q57374767-E1EEA686-5023-4E56-A979-D63ECCA0064E
title	In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab (en)
page(s)	wds:Q57374767-3E49DCEF-7D7C-43BC-BB5F-419296CAF2A3
page(s)	10556-10563
instance of	wds:Q57374767-2E7CE7E9-DAFF-4750-8DCE-244CE32A0AD3
instance of	scholarly article
main subject	wds:Q57374767-5CF779E5-100B-4211-B218-CD23069078DA wds:Q57374767-FEA5CEAB-8EA9-4129-9027-AA8450673FF0
main subject	antibody rituximab
PubMed ID	wds:Q57374767-A96D8503-11DB-416D-9B68-8445073F1BA2
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17975000
PubMed ID	17975000
published in	wds:Q57374767-4A1EF347-C8CD-43B3-B0F9-F12837F87784
published in	Cancer Research
issue	wds:Q57374767-9DBFDABE-44B4-43DE-9E4E-E129132476B3
volume	wds:Q57374767-672AF3F0-F326-4589-8D3C-78E3D3C17C1D
issue	21
volume	67
DOI	wds:Q57374767-ADB9D612-73E3-454A-B261-9C306F44F194
DOI	http://dx.doi.org/10.1158/0008-5472.CAN-07-1811
DOI	10.1158/0008-5472.CAN-07-1811
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57374767
is cites work of	Rituximab resistance Dynamic control of the complement system by modulated expression of regulatory proteins Mechanisms of action of CD20 antibodies Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles Gamma-delta T-cell lymphomas Ofatumumab, a human anti-CD20 monoclonal antibody CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells Protein engineering to target complement evasion in cancer Characterization of novel CD55 isoforms expression in normal and neoplastic tissues Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance An improved syngeneic orthotopic murine model of human breast cancer progression Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis Complement in cancer and cancer immunotherapy Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation. The future of CD20 monoclonal antibody therapy in B-cell malignancies Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma The good and evil of complement activation in HIV-1 infection Rapid degradation of the complement regulator, CD59, by a novel inhibitor Antigenic modulation and rituximab resistance Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster Targeting neural-restrictive silencer factor sensitizes tumor cells to antibody-based cancer immunotherapy in vitro via multiple mechanisms Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer Complement in monoclonal antibody therapy of cancer Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo Beyond the Role of CD55 as a Complement Component. Complement as a Biological Tool to Control Tumor Growth Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software